ライフサイエンスコーパス: acquired immunodeficiency

1 ell function is disrupted by an inherited or acquired immunodeficiency.

2 y the LP-BM5 retrovirus, which causes murine acquired immunodeficiency.

3 e disease, organ transplants, and primary or acquired immunodeficiencies.

4 pergillosis in children and adolescents with acquired immunodeficiencies and discusses the value of c

5 lignant neoplasias, cardiovascular diseases, acquired immunodeficiencies and other chronic diseases (

6 transplantation, in states of congenital or acquired immunodeficiency, and during normal aging.

7 In acquired immunodeficiency due to the human immunodeficie

8 individuals and in patients with genetic or acquired immunodeficiency (e.g., AIDS) or autoimmune dis

9 in the relative risk of death related to the acquired immunodeficiency syndrome (0.73; 95 percent con

10 uman immunodeficiency virus infection or the acquired immunodeficiency syndrome (7 percent each).

11 study, baseline plasma from 619 persons with acquired immunodeficiency syndrome (AIDS) (median CD4+ l

12 fect of injection drug use on 6-year risk of acquired immunodeficiency syndrome (AIDS) after initiati

13 To investigate the validity of self-reported acquired immunodeficiency syndrome (AIDS) among women en

14 ne their associations with incident clinical acquired immunodeficiency syndrome (AIDS) and CD4+ T cel

15 iciency virus (HIV)-infected men at risk for acquired immunodeficiency syndrome (AIDS) and followed b

16 gnificant reductions in the incidence of the acquired immunodeficiency syndrome (AIDS) and in mortali

17 T) has dramatically reduced the incidence of acquired immunodeficiency syndrome (AIDS) and increased

18 pontine myelinolysis), infections [malaria, acquired immunodeficiency syndrome (AIDS) and infection

19 es suggest a correlation between severity of acquired immunodeficiency syndrome (AIDS) and selenium d

20 Time to development of acquired immunodeficiency syndrome (AIDS) and time to de

21 In 1981, the acquired immunodeficiency syndrome (AIDS) appeared insid

22 Encephalitis and dementia associated with acquired immunodeficiency syndrome (AIDS) are characteri

23 ections of the biliary tree in patients with acquired immunodeficiency syndrome (AIDS) are well known

24 return visit to the clinic and being free of acquired immunodeficiency syndrome (AIDS) at enrollment.

25 ed 13 years or older who were diagnosed with acquired immunodeficiency syndrome (AIDS) between Januar

26 A total of 1600 participants with acquired immunodeficiency syndrome (AIDS) but without CM

27 mimic a clinical trial to assess the risk of acquired immunodeficiency syndrome (AIDS) by timing of t

28 quantify the cumulative survival benefits of acquired immunodeficiency syndrome (AIDS) care in the Un

29 ods for estimating the prevented fraction of acquired immunodeficiency syndrome (AIDS) cases attribut

30 lor represent an increasing proportion of US acquired immunodeficiency syndrome (AIDS) cases, few res

31 cterized for certain biliary diseases, e.g., acquired immunodeficiency syndrome (AIDS) cholangiopathy

32 Biliary cryptosporidiosis is associated with acquired immunodeficiency syndrome (AIDS) cholangiopathy

33 ession on CD8(+) T lymphocytes may relate to acquired immunodeficiency syndrome (AIDS) clinical progr

34 ficiency virus (HIV) infections and averting acquired immunodeficiency syndrome (AIDS) deaths in the

35 Declines in the number of acquired immunodeficiency syndrome (AIDS) deaths were fi

36 tions occurred in one patient (25%), all non-acquired immunodeficiency syndrome (AIDs) defining.

37 (HIV)-infected brain in relationship to the acquired immunodeficiency syndrome (AIDS) dementia compl

38 Progressive immune dysfunction and the acquired immunodeficiency syndrome (AIDS) develop in mos

39 human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS) epidemic has g

40 se to the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic is th

41 The effect of the acquired immunodeficiency syndrome (AIDS) epidemic on wo

42 Containment of the acquired immunodeficiency syndrome (AIDS) epidemic will

43 (HIV) vaccine is critical to end the global acquired immunodeficiency syndrome (AIDS) epidemic, but

44 Early in the acquired immunodeficiency syndrome (AIDS) epidemic, epid

45 networks in predicting rapid progression to acquired immunodeficiency syndrome (AIDS) for patients w

46 genes into both T cells and macrophages for acquired immunodeficiency syndrome (AIDS) gene therapy.

47 In contrast, persons with established acquired immunodeficiency syndrome (AIDS) had a signific

48 ndidate genes for stem cell gene therapy for acquired immunodeficiency syndrome (AIDS) has been limit

49 Persons with acquired immunodeficiency syndrome (AIDS) have a higher

50 ons with cytomegalovirus (CMV) retinitis and acquired immunodeficiency syndrome (AIDS) have required

51 r and was mainly due to the emergence of the acquired immunodeficiency syndrome (AIDS) in 25- to 64-y

52 eficiency virus type 1 (HIV-1), the cause of acquired immunodeficiency syndrome (AIDS) in humans, eff

53 SIVsm from sooty mangabeys, are the cause of acquired immunodeficiency syndrome (AIDS) in humans.

54 virus type 1 (HIV-1), the etiologic agent of acquired immunodeficiency syndrome (AIDS) in humans.

55 ently have focused on access to treatment of acquired immunodeficiency syndrome (AIDS) in poor, sever

56 mmunodeficiency virus (HIV) infection or the acquired immunodeficiency syndrome (AIDS) in sub-Saharan

57 n immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) in the federal

58 's Health Study (SFMHS); 268 men without the acquired immunodeficiency syndrome (AIDS) in the SFMHS w

59 iruses, however, SIVs do not generally cause acquired immunodeficiency syndrome (AIDS) in their natur

60 activation is a key factor in progression to acquired immunodeficiency syndrome (AIDS) in untreated H

61 Acquired immunodeficiency syndrome (AIDS) is principally

62 l leukoencephalopathy (PML) complicating the acquired immunodeficiency syndrome (AIDS) is typically i

63 As people with acquired immunodeficiency syndrome (AIDS) live longer, t

64 uals with a high viral set point progress to acquired immunodeficiency syndrome (AIDS) more rapidly t

65 To understand recent temporal trends in acquired immunodeficiency syndrome (AIDS) mortality in t

66 lative risk (RR) for clinical progression to acquired immunodeficiency syndrome (AIDS) of 1.66 (95% c

67 idemic of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) on demand for

68 gosity of class I loci (A, B, and C) delayed acquired immunodeficiency syndrome (AIDS) onset among pa

69 c millimeter or until the development of the acquired immunodeficiency syndrome (AIDS) or another con

70 hly active antiretroviral therapy on time to acquired immunodeficiency syndrome (AIDS) or death in 1,

71 iretroviral therapy initiation with incident acquired immunodeficiency syndrome (AIDS) or death while

72 ve antiretroviral therapy (HAART) on time to acquired immunodeficiency syndrome (AIDS) or death, the

73 re urgently needed to curb the growth of the acquired immunodeficiency syndrome (AIDS) pandemic and u

74 erapeutic strategies that aim to contain the acquired immunodeficiency syndrome (AIDS) pandemic.

75 The hallmark of acquired immunodeficiency syndrome (AIDS) pathogenesis i

76 V-infected populations compared with similar acquired immunodeficiency syndrome (AIDS) patients in th

77 This study reports the surgical outcomes of acquired immunodeficiency syndrome (AIDS) patients with

78 CSF samples from 15 acquired immunodeficiency syndrome (AIDS) patients with

79 entify cancers that occur at higher rates in acquired immunodeficiency syndrome (AIDS) patients, the

80 es persistent skin neoplasms in children and acquired immunodeficiency syndrome (AIDS) patients.

81 tivation and drives systemic inflammation in acquired immunodeficiency syndrome (AIDS) patients.

82 fection in a new host is a critical goal for acquired immunodeficiency syndrome (AIDS) research.

83 tion analysis of five cohorts of people with acquired immunodeficiency syndrome (AIDS) revealed that

84 Most acquired immunodeficiency syndrome (AIDS) service provid

85 ococcal disease incidence among persons with acquired immunodeficiency syndrome (AIDS) since the intr

86 reduced in alveolar macrophages and PMN from acquired immunodeficiency syndrome (AIDS) subjects, we i

87 The authors assessed temporal trends in acquired immunodeficiency syndrome (AIDS) survival for 1

88 age is associated with markedly enhanced HIV/acquired immunodeficiency syndrome (AIDS) susceptibility

89 iciency virus (HIV) among cases who obtained acquired immunodeficiency syndrome (AIDS) through hetero

90 nctively associated with communication about acquired immunodeficiency syndrome (AIDS) through social

91 esign, the authors compared 1,642 women with acquired immunodeficiency syndrome (AIDS) to 8,443 uninf

92 ted from monkeys with acute SIV infection or acquired immunodeficiency syndrome (AIDS) underwent norm

93 impact of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) versus other l

94 ed States-based natural-history cohorts with acquired immunodeficiency syndrome (AIDS) were genotyped

95 megalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) who are receiv

96 gous state, SDF1-3'A/3'A delays the onset of acquired immunodeficiency syndrome (AIDS), according to

97 affects about 4 percent of patients with the acquired immunodeficiency syndrome (AIDS), and survival

98 se to cryptosporidiosis in patients with the acquired immunodeficiency syndrome (AIDS), and went on t

99 tomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS), but it does n

100 redicts the likelihood of progression to the acquired immunodeficiency syndrome (AIDS), but the relat

101 ere followed from seroconversion to incident acquired immunodeficiency syndrome (AIDS), death, or the

102 ncy virus type 1 (HIV-1), the cause of human acquired immunodeficiency syndrome (AIDS), is a zoonotic

103 ciency virus type 1 (HIV-1) infection to the acquired immunodeficiency syndrome (AIDS), it appears th

104 udy was to measure, as a model of wasting in acquired immunodeficiency syndrome (AIDS), longitudinal

105 eases included in the case definition of the acquired immunodeficiency syndrome (AIDS), non-AIDS-defi

106 In addition to acquired immunodeficiency syndrome (AIDS), persons infec

107 reduced prevalence and mortality induced by acquired immunodeficiency syndrome (AIDS), provided the

108 inment of deaths among people diagnosed with acquired immunodeficiency syndrome (AIDS), the authors d

109 ctives on human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), tuberculosis

110 and immune activation predict progression to acquired immunodeficiency syndrome (AIDS), we evaluated

111 ly antiretroviral therapy, which can prevent acquired immunodeficiency syndrome (AIDS)-associated eve

112 Patients with acquired immunodeficiency syndrome (AIDS)-associated non

113 virus (SIV)-infected macaques as a model of acquired immunodeficiency syndrome (AIDS)-associated P.

114 The acquired immunodeficiency syndrome (AIDS)-causing lentiv

115 asures were death, the occurrence of a first acquired immunodeficiency syndrome (AIDS)-defining condi

116 carinii pneumonia was the initial (and only) acquired immunodeficiency syndrome (AIDS)-defining diagn

117 re divided by disease severity defined as an acquired immunodeficiency syndrome (AIDS)-defining event

118 Ten individuals developed acquired immunodeficiency syndrome (AIDS)-defining event

119 definition of LTF on estimated rates of LTF, acquired immunodeficiency syndrome (AIDS)-defining event

120 e antiretroviral therapy (HAART) on multiple acquired immunodeficiency syndrome (AIDS)-defining illne

121 did not have a new (previously undiagnosed) acquired immunodeficiency syndrome (AIDS)-defining illne

122 nemia was 36.9% for persons with one or more acquired immunodeficiency syndrome (AIDS)-defining oppor

123 o identify CD4(+) levels associated with the acquired immunodeficiency syndrome (AIDS)-free time equi

124 The acquired immunodeficiency syndrome (AIDS)-protective che

125 We assessed non-liver-related non-acquired immunodeficiency syndrome (AIDS)-related (NLR-N

126 from eight HCV-infected patients who died of acquired immunodeficiency syndrome (AIDS)-related compli

127 venues for investigating the pathogenesis of acquired immunodeficiency syndrome (AIDS)-related cytope

128 To determine whether microbiologic cure of acquired immunodeficiency syndrome (AIDS)-related dissem

129 and to determine the role that a hospital's acquired immunodeficiency syndrome (AIDS)-related experi

130 munodeficiency virus (HIV) have shifted from acquired immunodeficiency syndrome (AIDS)-related illnes

131 e 1 pilot study of IL-12 in 32 patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi

132 ARL (acquired immunodeficiency syndrome (AIDS)-related lympho

133 osing event in the early pathogenesis of the acquired immunodeficiency syndrome (AIDS)-related lympho

134 ffect of time-varying incident TB on time to acquired immunodeficiency syndrome (AIDS)-related mortal

135 in Kaposi's sarcoma (KS), as well as in some acquired immunodeficiency syndrome (AIDS)-related non-Ho

136 emonstrated that prior to the development of acquired immunodeficiency syndrome (AIDS)-related pulmon

137 mic" pediatric Burkitt's lymphomas (BL), two acquired immunodeficiency syndrome (AIDS)-related type I

138 the development of a preventive vaccine for acquired immunodeficiency syndrome (AIDS).

139 ficiency virus (SIV) very rarely progress to acquired immunodeficiency syndrome (AIDS).

140 proportional increases in incidence rates of acquired immunodeficiency syndrome (AIDS).

141 mon opportunistic infection of patients with acquired immunodeficiency syndrome (AIDS).

142 cterial infection in untreated patients with acquired immunodeficiency syndrome (AIDS).

143 function and its predictors in children with acquired immunodeficiency syndrome (AIDS).

144 may cause chronic diarrhea in patients with acquired immunodeficiency syndrome (AIDS).

145 ied cocaine as a cofactor for development of acquired immunodeficiency syndrome (AIDS).

146 trointestinal disease are common features of acquired immunodeficiency syndrome (AIDS).

147 galovirus retinitis in 160 patients with the acquired immunodeficiency syndrome (AIDS).

148 ant declines in morbidity and mortality from acquired immunodeficiency syndrome (AIDS).

149 ents with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome (AIDS).

150 o be a cofactor in the immunopathogenesis of acquired immunodeficiency syndrome (AIDS).

151 HIV infection, is a principal driver of the acquired immunodeficiency syndrome (AIDS).

152 mal viral infectivity and the progression to acquired immunodeficiency syndrome (AIDS).

153 macular degeneration (AMD) in patients with acquired immunodeficiency syndrome (AIDS).

154 atment of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS).

155 t complication of pneumonia in patients with acquired immunodeficiency syndrome (AIDS).

156 ollowing adoptive transfer to a patient with acquired immunodeficiency syndrome (AIDS).

157 sexually transmitted diseases, including the acquired immunodeficiency syndrome (AIDS).

158 er viral loads and more rapid progression to acquired immunodeficiency syndrome (AIDS).

159 of morbidity and mortality in patients with acquired immunodeficiency syndrome (AIDS).

160 s of opportunistic infections related to the acquired immunodeficiency syndrome (AIDS).

161 e and non-Hodgkin's lymphomas related to the acquired immunodeficiency syndrome (AIDS).

162 morbidity and mortality associated with the acquired immunodeficiency syndrome (AIDS).

163 groups: adults and children with and without acquired immunodeficiency syndrome (AIDS).

164 ersistent infections in humans which lead to acquired immunodeficiency syndrome (AIDS).

165 tomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS).

166 n intraocular infection in patients with the acquired immunodeficiency syndrome (AIDS).

167 driving force of CD4(+) T-cell depletion and acquired immunodeficiency syndrome (AIDS).

168 actor for HIV-1 infection and progression to acquired immunodeficiency syndrome (AIDS).

169 of the stomach and esophagus in people with acquired immunodeficiency syndrome (AIDS).

170 the main target for design of drugs against acquired immunodeficiency syndrome (AIDS).

171 th species-specific SIVs, but do not develop acquired immunodeficiency syndrome (AIDS).

172 infection since the earliest recognition of acquired immunodeficiency syndrome (AIDS).

173 Five patients had acquired immunodeficiency syndrome (AIDS); one had commo

174 orbid human immunodeficiency virus infection/acquired immunodeficiency syndrome (HIV/AIDS) (OR = 4.27

175 h has scaled-up human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care and t

176 Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) is one of

177 ch as diabetes, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), arthritis

178 illimeter or if an illness indicative of the acquired immunodeficiency syndrome (i.e., an AIDS-defini

179 0, CI 0.28-0.57) and increased with comorbid acquired immunodeficiency syndrome (OR 4.52, CI 3.01-6.7

180 lementation has on the progression of simian acquired immunodeficiency syndrome (SAIDS).

181 ders, and infectious diseases (excluding the acquired immunodeficiency syndrome [AIDS]), many of whic

182 ed with an immunodeficiency syndrome (simian acquired immunodeficiency syndrome [SAIDS]) caused by a

183 Fifty-nine percent had the acquired immunodeficiency syndrome according to the case

184 interferon (rIFN)- gamma 1b in patients with acquired immunodeficiency syndrome and acute cryptococca

185 from culture isolates from 87 patients with acquired immunodeficiency syndrome and CMV retinitis who

186 rnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis.

187 they had an increased risk of progression to acquired immunodeficiency syndrome and death, a relation

188 sis is classically reported in patients with acquired immunodeficiency syndrome and emerged as a caus

189 regular alcohol consumption (one of whom had acquired immunodeficiency syndrome and hepatitis B), one

190 and clinical parameters among patients with acquired immunodeficiency syndrome and histoplasmosis in

191 ts with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious

192 rden created by human immunodeficiency virus/acquired immunodeficiency syndrome and other infectious

193 rates of incarceration and reported cases of acquired immunodeficiency syndrome and syphilis were wea

194 Records of people diagnosed with acquired immunodeficiency syndrome between 1993 and 2007

195 TB accelerates acquired immunodeficiency syndrome by increasing human i

196 to develop immunotherapeutic strategies for acquired immunodeficiency syndrome capable of activating

197 he basic package of services provided by HIV/acquired immunodeficiency syndrome care and treatment pr

198 In patients with sclerosing cholangitis and acquired immunodeficiency syndrome cholangiopathy, MRCP

199 s were enrolled at 28 sites of the Pediatric Acquired Immunodeficiency Syndrome Clinical Trials Group

200 men who were participants in the Multicenter Acquired Immunodeficiency Syndrome Cohort Study for GBV-

201 es brain function and presents clinically as acquired immunodeficiency syndrome dementia complex (ADC

202 vanced immunodeficiency, all 4 subjects with acquired immunodeficiency syndrome dementia complex had

203 The proportion of acquired immunodeficiency syndrome diagnoses in which wa

204 Having an acquired immunodeficiency syndrome diagnosis or multiple

205 ntigen genetic association with HIV-1 and/or acquired immunodeficiency syndrome disease progression i

206 fies clinical presentation in the era of the acquired immunodeficiency syndrome epidemic.

207 rus type 1 (HIV-1) and those affected by the acquired immunodeficiency syndrome epidemic.

208 ted from 2 ALIVE scientists and an expert in acquired immunodeficiency syndrome epidemiology about th

209 r patients attending a county outpatient HIV/acquired immunodeficiency syndrome facility were referre

210 ciency virus (HIV)-infected subjects without acquired immunodeficiency syndrome have a high frequency

211 Although the incidence of and mortality from acquired immunodeficiency syndrome have declined recentl

212 t the LP-BM5 murine leukemia virus causes an acquired immunodeficiency syndrome in C57BL/6 mice (MAID

213 etermine the feasibility of gene therapy for acquired immunodeficiency syndrome in individuals alread

214 rculosis is often the first manifestation of acquired immunodeficiency syndrome in patients infected

215 gene therapy strategies for diseases such as acquired immunodeficiency syndrome is limited.

216 cted injection drug users recruited into the Acquired Immunodeficiency Syndrome Link to Intravenous E

217 Deaths from acquired immunodeficiency syndrome occurred exclusively

218 to initiate therapy prior to progression to acquired immunodeficiency syndrome or death by both meas

219 ts of dropout, the weighted hazard ratio for acquired immunodeficiency syndrome or death comparing us

220 ly active antiretroviral therapy on incident acquired immunodeficiency syndrome or death, the authors

221 active antiretroviral therapy, 211 developed acquired immunodeficiency syndrome or died, and 173 drop

222 r patients with human immunodeficiency virus/acquired immunodeficiency syndrome or substance abuse (f

223 ings has begun to mitigate the impact of the acquired immunodeficiency syndrome pandemic.

224 anciclovir has become increasingly common in acquired immunodeficiency syndrome patients but has only

225 the spinal cord dorsal horn (SDH) from HIV-1/acquired immunodeficiency syndrome patients who develope

226 revious serologic diagnosis of HIV, from the acquired immunodeficiency syndrome program of the Health

227 subtyping is not integrated into routine HIV/acquired immunodeficiency syndrome surveillance in the U

228 virus induces a complex disease featuring an acquired immunodeficiency syndrome termed murine AIDS (M

229 aracterized by slower disease progression to acquired immunodeficiency syndrome than results from HIV

230 eficiency virus (HIV) protease inhibitors in acquired immunodeficiency syndrome therapy.

231 relevance of their epitopes in the design of acquired immunodeficiency syndrome vaccines.

232 tions of measles in the setting of a chronic acquired immunodeficiency syndrome virus infection.

233 eys were used to clarify the distribution of acquired immunodeficiency syndrome virus-specific cytoto

234 The acquired immunodeficiency syndrome was the major cause o

235 age of > 10% and a positive association with acquired immunodeficiency syndrome were borderline signi

236 R, 0.2; 95% CI, 0.03-0.9), but patients with acquired immunodeficiency syndrome were more likely to r

237 eukemia, lymphoma, severe liver disease, and acquired immunodeficiency syndrome were rarely identifie

238 ination of brain tissue from 2 patients with acquired immunodeficiency syndrome who had CMV encephali

239 chieving immune restoration in patients with acquired immunodeficiency syndrome who have incomplete r

240 8 lymphocytes/mm(3)), 90 (18%) progressed to acquired immunodeficiency syndrome within 5 years.

241 st a close friend or intimate partner to the acquired immunodeficiency syndrome within the prior 6 mo

242 inhibitors against HIV, the culprit of AIDS (acquired immunodeficiency syndrome).

243 ed ART; 5 patients died (unrelated to HIV or acquired immunodeficiency syndrome).

244 5,321 person-years, 268 of 614 men incurred acquired immunodeficiency syndrome, 49 died, and 90 were

245 load after infection and 5-year incidence of acquired immunodeficiency syndrome, adjusting for (conti

246 eme Court's first case involving HIV and the acquired immunodeficiency syndrome, Bragdon v Abbott, ad

247 However, the acquired immunodeficiency syndrome, breast cancer, diabe

248 en-group differences in the incidence of the acquired immunodeficiency syndrome, death, or serious ad

249 tors for NTS, including autoimmune diseases, acquired immunodeficiency syndrome, diabetes, cirrhosis,

250 type 1 reduces the mortality of persons with acquired immunodeficiency syndrome, it does not eliminat

251 In nonhuman primate models of acquired immunodeficiency syndrome, live attenuated lent

252 man immunodeficiency virus infection and the acquired immunodeficiency syndrome, medical malpractice,

253 g patients with human immunodeficiency virus/acquired immunodeficiency syndrome, patients receiving t

254 n human immunodeficiency virus infection and acquired immunodeficiency syndrome, rheumatoid arthritis

255 The mean reporting completeness for acquired immunodeficiency syndrome, sexually transmitted

256 In acquired immunodeficiency syndrome, the retina is a majo

257 rvum is a major problem in patients with the acquired immunodeficiency syndrome, the specific microbi

258 the worldwide health problems caused by the acquired immunodeficiency syndrome, tuberculosis, and ma

259 uman immunodeficiency virus infection or the acquired immunodeficiency syndrome, were referred to the

260 s, malaria, and human immunodeficiency virus/acquired immunodeficiency syndrome, with significant res

261 fection causes an AIDS-like syndrome--murine acquired immunodeficiency syndrome--in C57B1/6 mice and

262 to neonatal infection, transplantation, and acquired immunodeficiency syndrome-associated CMV diseas

263 The acquired immunodeficiency syndrome-associated lymphoma A

264 reducing the disease burden in patients with acquired immunodeficiency syndrome-associated tuberculos

265 00 x 10(6)/L and 549 x 10(6)/L without prior acquired immunodeficiency syndrome-defining conditions r

266 ficantly higher for patients without a prior acquired immunodeficiency syndrome-defining illness and

267 tion, whereas patients who developed another acquired immunodeficiency syndrome-defining illness did

268 s were used to determine predictors of a new acquired immunodeficiency syndrome-defining illness or d

269 nts with Medicaid, and patients with a prior acquired immunodeficiency syndrome-defining illness were

270 infection and CIN, and cervical cancer is an acquired immunodeficiency syndrome-defining illness.

271 r, and 65 percent of the patients had had an acquired immunodeficiency syndrome-defining illness.

272 ive multifocal leukoencephalopathy (PML), an acquired immunodeficiency syndrome-defining illness.

273 1984-2008, regarding estimation of long-term acquired immunodeficiency syndrome-free survival to demo

274 ococcal meningitis accounts for 20 to 25% of acquired immunodeficiency syndrome-related deaths in Afr

275 imately 25% of patients with newly diagnosed acquired immunodeficiency syndrome-related lymphoma (ARL

276 ived a heterologous stem cell transplant for acquired immunodeficiency syndrome-related lymphoma from

277 The outcome of acquired immunodeficiency syndrome-related lymphomas (AR

278 Recent dramatic decreases in acquired immunodeficiency syndrome-related mortality are

279 was used to evaluate the effect of HAART on acquired immunodeficiency syndrome-related mortality, ad

280 Because the incidence of traditional acquired immunodeficiency syndrome-related opportunistic

281 compromised patients with cancer or advanced acquired immunodeficiency syndrome.

282 (>/=2 symptoms), and deaths were ascribed to acquired immunodeficiency syndrome.

283 al failure, and human immunodeficiency virus/acquired immunodeficiency syndrome.

284 voirs for viral persistence in patients with acquired immunodeficiency syndrome.

285 carinii DHPS mutations in 107 patients with acquired immunodeficiency syndrome.

286 as been approved by the FDA for treatment of acquired immunodeficiency syndrome.

287 larly in the context of immunodeficiency and acquired immunodeficiency syndrome.

288 n immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome.

289 iciency virus infection and delayed onset of acquired immunodeficiency syndrome.

290 regenerative states, immune cytopenias, and acquired immunodeficiency syndrome.

291 ts have been described only in patients with acquired immunodeficiency syndrome.

292 on opportunistic infections in patients with acquired immunodeficiency syndrome.

293 ing to the vascular injury syndromes seen in acquired immunodeficiency syndrome.

294 rus infection, particularly in patients with acquired immunodeficiency syndrome.

295 h cytomegalovirus-associated esophagitis and acquired immunodeficiency syndrome.

296 er nonmalignant CNS lesions in patients with acquired immunodeficiency syndrome.

297 cell counts <350 cells/mm(3) and 2 (7%) had acquired immunodeficiency syndrome.

298 ciency virus (SIV)-infected macaque model of acquired immunodeficiency syndrome.

299 using SSRI treatment adjunctively in HIV and acquired immunodeficiency syndrome.

300 re much rarer than TB, but the inherited and acquired immunodeficiencies underlying these infections